PT  - JOURNAL ARTICLE
AU  - Christian Schmidkonz
AU  - Torsten Kuwert
AU  - Armin Atzinger
AU  - Michael Cordes
AU  - Georg Schett
AU  - Andreas Ramming
AU  - Theresa Götz
TI  - Fibroblast Activation Protein Inhibitor Imaging in Nonmalignant Diseases: A New Perspective for Molecular Imaging
AID  - 10.2967/jnumed.122.264205
DP  - 2022 Dec 01
TA  - Journal of Nuclear Medicine
PG  - 1786--1792
VI  - 63
IP  - 12
4099  - http://jnm.snmjournals.org/content/63/12/1786.short
4100  - http://jnm.snmjournals.org/content/63/12/1786.full
SO  - J Nucl Med2022 Dec 01; 63
AB  - Fibroblast activation protein-α (FAP-α) is a type II transmembrane glycoprotein that is overexpressed in activated fibroblasts such as those in the stroma of tumors or in the fibrotic processes accompanying various benign diseases. The recent development and clinical implementation of radiolabeled quinolone-based tracers suitable for PET that act as FAP inhibitors (FAPIs) have opened a new perspective in molecular imaging. Although multiple studies have investigated the use of FAPI imaging in cancer, evidence concerning its use in nonmalignant diseases is still scarce. Herein, we provide a comprehensive review of FAPI imaging in nonmalignant diseases to clarify the current and potential role of this class of molecules in nuclear medicine.